ClinicalTrials.gg
TerminatedNCT00017069Updated Oct 5, 2020

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

A Phase 2 interventional study of arsenic trioxide and dexamethasone in Multiple Myeloma and Plasma Cell Neoplasm, sponsored by CTI BioPharma. Terminated at 10 sites in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2020-10-05.

Sponsored by CTI BioPharma (part of Swedish Orphan Biovitrum) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Feb 2001, registered Jun 2001).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing Arsenic Trioxide in Multiple Myeloma — none open to participants now, none under way, none of them phase 3. Arsenic Trioxide · Multiple Myeloma.

Started
2001
with 1 other
Phase 2
8 of 16
none open now
Registered
5th of 16
by date
Lead sponsor
2 of 16
CTI BioPharma

Among the 16 studies testing Arsenic Trioxide in Multiple Myeloma, this one is one of 2 that started in 2001, is one of 8 in phase 2, and was the 5th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

None of the 16 studies testing Arsenic Trioxide in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →

Where they have run

About Arsenic Trioxide

Arsenic Trioxide: first FDA approval 2000 (TRISENOX), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing Arsenic Trioxide in Multiple Myeloma as a file.
02

Study summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combining arsenic trioxide and dexamethasone in treating patients who have recurrent or refractory stage II or stage III multiple myeloma.

Read the detailed description

OBJECTIVES:

  • Determine the response rate of patients with recurrent or refractory stage II or III multiple myeloma treated with arsenic trioxide and dexamethasone.
  • Determine the rates of overall and relapse-free survival in patients treated with this regimen.
  • Determine the safety profile of this treatment regimen in these patients.

OUTLINE: Patients receive arsenic trioxide IV daily for 5 days during the first week only and then 2 days a week thereafter. Patients also receive IV or oral dexamethasone on days 1-4 every 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Disease assessments are conducted every 4 weeks. Patients achieving complete response (CR) receive 2 additional courses of therapy after initial determination of CR.

Final assessments are conducted 4 weeks after the last study treatment and then annually thereafter.

PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study.

03

Conditions studied

  • Multiple Myeloma and Plasma Cell Neoplasm

Keywords

  • refractory multiple myeloma
  • stage II multiple myeloma
  • stage III multiple myeloma
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of stage II or III multiple myeloma
  • myeloma defined as progressive disease (more than 25% increase in M protein or in radiographic findings of nonsecretory myeloma) despite up to 3 courses of prior cytotoxic chemotherapy

    • No more than 3 prior cytotoxic regimens
    • No more than 1 prior high-dose cytotoxic regimen with stem cell transplantation
  • History of disease progression after prior antimyeloma therapy
  • No smoldering myeloma
  • based on presence of serum and urine M protein and/or measurable plasmacytoma

PATIENT CHARACTERISTICS:

Age:

  • Over 18

Performance status:

  • 70-100%

:

  • At least 3 months

Hematopoietic:

  • Absolute granulocyte count greater than 1,200/mm\^3*
  • count greater than 75,000/mm\^3*
  • greater than 10 g/dL* NOTE: *Unless due to multiple myeloma

Hepatic:

  • no greater than 2 times (ULN)
  • and SGPT no greater than 2 times ULN

Renal:

  • Creatinine no greater than 1.5 times ULN

Cardiovascular:

  • Absolute less than 460 msec in the presence of normal potassium and magnesium levels
  • No significant underlying cardiac dysfunction
  • No conduction defects
  • No unstable angina
  • No congestive heart failure
  • No class II-IV cardiac disease
  • No myocardial infarction within the past 6 months

Other:

  • No preexisting grade 2 or greater neurotoxicity/neuropathy
  • No other within the past 5 years except curatively treated carcinoma in situ of the cervix or nonmelanoma skin cancer
  • No uncontrolled diabetes mellitus
  • No active serious infection uncontrolled by antibiotics
  • No history of grand mal seizures (other than infantile febrile seizures)
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • See Disease Characteristics
  • See Chemotherapy
  • At least 28 days since prior biologic therapy

Chemotherapy:

  • See Disease Characteristics
  • At least 28 days since prior cytotoxic chemotherapy, including high-dose cytotoxic regimen with stem cell transplantation
  • No other concurrent cytotoxic chemotherapy

Endocrine therapy:

  • See Disease Characteristics

Radiotherapy:

  • At least 28 days since prior radiotherapy except for focal radiation for symptom control

Surgery:

  • Not specified
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Masking
None (open label)

Interventions

06

Study locations

10 sites
  • Arizona Clinical Research Center
    Tucson, Arizona 85712, United States
  • Highlands Oncology Group - Springdale
    Springdale, Arkansas 72764, United States
  • St. Joseph Hospital Regional Cancer Center - Orange
    Orange, California 92868-3849, United States
  • Stockton Hematology Oncology Medical Group
    Stockton, California 95204, United States
  • Rocky Mountain Cancer Centers - Midtown
    Denver, Colorado 80218, United States
  • Pasco Pinellas Cancer Center - Tarpon Springs
    Tarpon Springs, Florida 34689, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Mountain States Tumor Institute - Boise
    Meridian, Idaho 83642, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021, United States
  • Texas Cancer Care
    Fort Worth, Texas 76104, United States
07

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2001 to primary completion in Jan 2005, 47 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2001
First posted
Jan 27, 2003
StartActual
Feb 2001
Primary completionActual
Jan 2005
CompletionActual
Jan 2005
Last update
Oct 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00017069
Lead sponsor
CTI BioPharma
First posted
Jan 27, 2003
Start date
Feb 2001
Primary completion
Jan 2005
Completion
Jan 2005
Last update
Oct 5, 2020

Study contacts

Scott C. Stromatt, MD
study chair · CTI BioPharma
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Arsenic Trioxide · Dexamethasone

Start the discussion